18 years to 55 years
Seeking healthy male participants who do not have any history of asthma or hayfever.
The purpose of this study is to investigate a new asthma medication, though at this early stage of the research we require healthy participants who do not have asthma.
Asthma is a breathing condition, people with asthma have sensitive airways in their lungs which causes breathing difficulties. This condition has various causes, one such cause being allergies.
This is a Biosimilar study, which means that the new drug is almost an identical copy of an already approved drug manufactured by a different company, in this case the approved drug is called Omalizumab (Xolair®) for treatment of allergic asthma. This study will involve either the administration of the approved reference product (omalizumab) or the new comparison product. Omaluzimab is a registered drug and has been used in many patients for the treatment of asthma and urticaria. Omalizumab is an approved medication for the treatment of asthma in countries such as US, Australia and Europe.
There is currently only one treatment option of this type available to asthma patients (Xolair®). If approved, this new medication will widen their treatment options.
Phone Number: 1800 243 733
Location: 89 Commercial Road, Melbourne VIC, Australia
Approved By: Bellberry Limited
Clinical Trial Registry Link: